KR20200008580A - 중추 신경계에서의 암을 치료하기 위한 항-b7h3 항체의 용도 - Google Patents

중추 신경계에서의 암을 치료하기 위한 항-b7h3 항체의 용도 Download PDF

Info

Publication number
KR20200008580A
KR20200008580A KR1020197036884A KR20197036884A KR20200008580A KR 20200008580 A KR20200008580 A KR 20200008580A KR 1020197036884 A KR1020197036884 A KR 1020197036884A KR 20197036884 A KR20197036884 A KR 20197036884A KR 20200008580 A KR20200008580 A KR 20200008580A
Authority
KR
South Korea
Prior art keywords
antigen
antibody
binding fragment
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197036884A
Other languages
English (en)
Korean (ko)
Inventor
킴 크레이머
층 나이-콩
올레 베스가드
산-페드로 클라우스 제이. 묄러
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
와이-맙스 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터, 와이-맙스 테라퓨틱스 인코포레이티드 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20200008580A publication Critical patent/KR20200008580A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
KR1020197036884A 2017-05-12 2018-05-14 중추 신경계에서의 암을 치료하기 위한 항-b7h3 항체의 용도 Ceased KR20200008580A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505558P 2017-05-12 2017-05-12
US62/505,558 2017-05-12
PCT/US2018/032559 WO2018209346A1 (en) 2017-05-12 2018-05-14 Use of anti-b7h3 antibodies for treating cancer in the central nervous system

Publications (1)

Publication Number Publication Date
KR20200008580A true KR20200008580A (ko) 2020-01-28

Family

ID=64102794

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036884A Ceased KR20200008580A (ko) 2017-05-12 2018-05-14 중추 신경계에서의 암을 치료하기 위한 항-b7h3 항체의 용도

Country Status (11)

Country Link
US (2) US20200197546A1 (https=)
EP (1) EP3635012A4 (https=)
JP (2) JP2020520382A (https=)
KR (1) KR20200008580A (https=)
CN (1) CN110799542A (https=)
AU (1) AU2018265888A1 (https=)
BR (1) BR112019023776A2 (https=)
CA (1) CA3062335A1 (https=)
EA (1) EA201992683A1 (https=)
RU (1) RU2019140833A (https=)
WO (1) WO2018209346A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916265A (zh) * 2020-04-24 2023-04-04 Y-单克隆抗体制药有限公司 带有螯合剂的b7h3抗体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185897A1 (en) * 2019-03-11 2020-09-17 Biocompatibles Uk Limited Radioactive microshperes for the treatment of cns tumours
WO2021037319A1 (en) 2019-08-30 2021-03-04 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
WO2021190586A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
CN117024591A (zh) * 2020-04-22 2023-11-10 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
CN112961242B (zh) * 2020-06-30 2022-01-04 广州百暨基因科技有限公司 抗b7h3抗体及其应用
WO2022167052A1 (en) * 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
MX2023008895A (es) 2021-02-09 2023-08-09 Medilink Therapeutics Suzhou Co Ltd Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
WO2022232392A2 (en) * 2021-04-28 2022-11-03 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
CN116867805A (zh) * 2021-09-27 2023-10-10 盛禾(中国)生物制药有限公司 一种异源二聚体蛋白质及其应用
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
CN119744270A (zh) * 2022-07-08 2025-04-01 盛禾(中国)生物制药有限公司 一种异源二聚体融合蛋白及其应用
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP2010523478A (ja) * 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR102485788B1 (ko) * 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
US9963509B2 (en) * 2014-12-23 2018-05-08 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916265A (zh) * 2020-04-24 2023-04-04 Y-单克隆抗体制药有限公司 带有螯合剂的b7h3抗体

Also Published As

Publication number Publication date
US20240415990A1 (en) 2024-12-19
AU2018265888A1 (en) 2019-11-21
JP2020520382A (ja) 2020-07-09
EP3635012A1 (en) 2020-04-15
EP3635012A4 (en) 2020-12-30
EA201992683A1 (ru) 2020-04-23
RU2019140833A3 (https=) 2022-02-07
BR112019023776A2 (pt) 2020-07-28
JP2023016969A (ja) 2023-02-02
CA3062335A1 (en) 2018-11-15
CN110799542A (zh) 2020-02-14
US20200197546A1 (en) 2020-06-25
RU2019140833A (ru) 2021-06-15
WO2018209346A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
US20240415990A1 (en) Use of anti-b7h3 antibodies for treating cancer in the central nervous system
JP7592654B2 (ja) ヒト化抗カリクレイン－２抗体
JP5155356B2 (ja) モノクローナル抗体ｈＰＡＭ４
KR101002443B1 (ko) Ｒｓ7 항체
JP5110768B2 (ja) モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用
US11427648B2 (en) Anti-CD146 antibodies and uses thereof
Liu et al. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model
JP7274646B2 (ja) 血液悪性疾患を処置するための低用量抗体に基づく方法
JP6917357B2 (ja) 癌治療に使用する放射標識抗体断片
JP2026506001A (ja) 免疫ｐｅｔ撮像のための放射性標識された抗ｌａｇ３抗体
TW202417489A (zh) 使用抗ｃｌｄｎ１８．２抗體—放射性核種結合物之非侵入性方法
JP2008540429A (ja) 癌の治療における併用療法
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
WO2024183634A1 (en) Radiolabeled antibody conjugates and uses thereof
WO2012032043A1 (en) 212 pb imaging
Weber et al. Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model
Wolden Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Gregory et al. Radioimmunotherapy with engineered antibody fragments
IL165752A (en) Chimeric monoclonal antibody pam4, a conjugate comprising it and an antibody comprising the same or fragments thereof
IL165753A (en) HUMANIZED MONOCLONAL ANTIBODY hPAM4, A CONJUGATE COMPRISING IT AND AN ANTIBODY COMPRISING THE SAME OR FRAGMENTS THEREOF
HK1125030B (en) Rs7 antibodies
HK1125030A (en) Rs7 antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000